Severe asthma in the era of COVID-19

Detalhes bibliográficos
Autor(a) principal: Gaspar-Marques, João
Data de Publicação: 2021
Outros Autores: van Zeller, Mafalda, Carreiro-Martins, Pedro, Chaves Loureiro, Cláudia
Tipo de documento: Outros
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/119322
Resumo: Funding Information: João Gaspar Marques has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, Novartis, Sanofi and TEVA. Mafalda van Zeller has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and TEVA. Pedro Carreiro Martins has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. Cláudia Chaves Loureiro has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi and TEVA. Publisher Copyright: © 2021 Sociedade Portuguesa de Pneumologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
id RCAP_243eeb62e9ac7ec545b4e5720adb1340
oai_identifier_str oai:run.unl.pt:10362/119322
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Severe asthma in the era of COVID-19A narrative reviewAntibodiesAsthmaCovid-19MonoclonalSARS-CoV-2Pulmonary and Respiratory MedicineFunding Information: João Gaspar Marques has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, Novartis, Sanofi and TEVA. Mafalda van Zeller has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and TEVA. Pedro Carreiro Martins has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. Cláudia Chaves Loureiro has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi and TEVA. Publisher Copyright: © 2021 Sociedade Portuguesa de Pneumologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.Introduction and objectives: Severe asthma management during the coronavirus disease 2019 (COVID-19) pandemic is a challenge and will continue to be, at least in the next few months, as herd immunity is still a mirage. A lot has to be learned about how COVID-19 affects underlying diseases, and severe asthma is no exception. Methods: Narrative review of papers available until February 2021 in PubMed and Google Scholar, relating severe asthma and COVID-19. Four main research topics were reviewed: SARS-CoV-2 infection: immunology and respiratory pathology; interrelationship of severe asthma endotypes and COVID-19 disease mechanisms; severe asthma epidemiology and COVID-19; and biologics for severe asthma in the context of COVID-19. Results: COVID-19 disease mechanisms start with upper respiratory cell infection, and afterwards several immunological facets are activated, contributing to disease severity, namely cell-mediated immunity and antibody production. Although infrequent in the COVID-19 course some patients develop a cytokine storm that causes organ damage and may lead to acute respiratory distress syndrome or multiorgan failure. Regarding severe asthma endotypes, type2-high might have a protective role both in infection risk and disease course. There is conflicting data regarding the epidemiological relationship between COVID-19 among severe asthma patients, with some studies reporting increased risk of infection and disease course, whereas others the other way round. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19, although further evidence is needed. Conclusions: Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-home administration program.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Comprehensive Health Research Centre (CHRC) - pólo NMSRUNGaspar-Marques, Joãovan Zeller, MafaldaCarreiro-Martins, PedroChaves Loureiro, Cláudia2021-06-15T22:21:22Z2022-01-012022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/119322eng2531-0429PURE: 31941707https://doi.org/10.1016/j.pulmoe.2021.04.001info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:53:46Zoai:run.unl.pt:10362/119322Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:53:46Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Severe asthma in the era of COVID-19
A narrative review
title Severe asthma in the era of COVID-19
spellingShingle Severe asthma in the era of COVID-19
Gaspar-Marques, João
Antibodies
Asthma
Covid-19
Monoclonal
SARS-CoV-2
Pulmonary and Respiratory Medicine
title_short Severe asthma in the era of COVID-19
title_full Severe asthma in the era of COVID-19
title_fullStr Severe asthma in the era of COVID-19
title_full_unstemmed Severe asthma in the era of COVID-19
title_sort Severe asthma in the era of COVID-19
author Gaspar-Marques, João
author_facet Gaspar-Marques, João
van Zeller, Mafalda
Carreiro-Martins, Pedro
Chaves Loureiro, Cláudia
author_role author
author2 van Zeller, Mafalda
Carreiro-Martins, Pedro
Chaves Loureiro, Cláudia
author2_role author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Comprehensive Health Research Centre (CHRC) - pólo NMS
RUN
dc.contributor.author.fl_str_mv Gaspar-Marques, João
van Zeller, Mafalda
Carreiro-Martins, Pedro
Chaves Loureiro, Cláudia
dc.subject.por.fl_str_mv Antibodies
Asthma
Covid-19
Monoclonal
SARS-CoV-2
Pulmonary and Respiratory Medicine
topic Antibodies
Asthma
Covid-19
Monoclonal
SARS-CoV-2
Pulmonary and Respiratory Medicine
description Funding Information: João Gaspar Marques has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, Novartis, Sanofi and TEVA. Mafalda van Zeller has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and TEVA. Pedro Carreiro Martins has received research grants from AstraZeneca and honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis and Sanofi. Cláudia Chaves Loureiro has received honorarium as speaker/consultant from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi and TEVA. Publisher Copyright: © 2021 Sociedade Portuguesa de Pneumologia Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
publishDate 2021
dc.date.none.fl_str_mv 2021-06-15T22:21:22Z
2022-01-01
2022-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/119322
url http://hdl.handle.net/10362/119322
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2531-0429
PURE: 31941707
https://doi.org/10.1016/j.pulmoe.2021.04.001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545804351537152

Registros relacionados